**Background of TGM7 Antibody**
Transglutaminase 7 (TG7), encoded by the *TGM7* gene, belongs to the transglutaminase enzyme family, which catalyzes protein crosslinking via ε-(γ-glutamyl)lysine bonds. While other transglutaminases (e.g., TG2 in celiac disease) are well-studied, TG7 remains less characterized. It is primarily expressed in epithelial tissues, including the skin and gastrointestinal tract, suggesting roles in barrier function and cellular differentiation.
TGM7 antibodies are tools used to investigate TG7's expression, localization, and function. Research indicates TG7 may contribute to keratinocyte differentiation in the skin and mucosal surfaces, but its precise biological and pathological roles are unclear. Some studies link TG7 autoantibodies to rare autoimmune conditions, such as dermatitis herpetiformis or neurological disorders, though evidence is preliminary.
Commercial TGM7 antibodies are typically developed in rabbits or mice, targeting specific epitopes (e.g., N-terminal regions). They are employed in techniques like Western blotting, immunohistochemistry, or ELISA to study TG7 in disease models or normal physiology. Challenges include ensuring antibody specificity due to structural homology among transglutaminases. Ongoing research aims to clarify TG7's involvement in tissue homeostasis, inflammation, and its potential as a diagnostic or therapeutic target.